Kumar, RadhikaDohlman, ClaesChodosh, James2013-04-082012Kumar, Radhika, Claes H Dohlman, and James Chodosh. 2012. Oral acetazolamide after Boston keratoprosthesis in Stevens Johnson syndrome. BMC Research Notes 5: 205.1756-0500http://nrs.harvard.edu/urn-3:HUL.InstRepos:10512594Background: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare but severe and sometimes fatal condition associated with exposure to medications; sulfamethoxazole is among the most common causes. We sought to address the safety of acetazolamide, a chemically related compound, in patients with prior SJS/TEN and glaucoma. A retrospective case series is described of patients at the Massachusetts Eye and Ear Infirmary who underwent keratoprosthesis surgery for corneal blindness from SJS/TEN, and later required oral acetazolamide for elevated intraocular pressure. Findings: Over the last 10 years, 17 patients with SJS/TEN received a Boston keratoprosthesis. Of these, 11 developed elevated intraocular pressure that required administration of oral acetazolamide. One of 11 developed a mild allergic reaction, but no patient experienced a recurrence of SJS/TEN or any severe adverse reaction. Conclusion: Although an increase in the rate of recurrent SJS/TEN due to oral acetazolamide would not necessarily be apparent after treating only 11 patients, in our series, acetazolamide administration was well tolerated without serious sequela.en-USStevens Johnson syndromeToxic epidermal necrolysisAcetazolamideGlaucomaJournal Article2013-04-0810.1186/1756-0500-5-205